Infiltration of CD14-positive macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis.
Makoto Kinouchia, Koh Miurab, Takayuki Mizoib, Kazuyuki Ishida, Wataru Fujibuchic, Toshinori Ando, Nobuki Yazaki, Kazuya Saitod, Ken-ichi Shiibab, Iwao Sasakie
- aDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
- bTohoku University, Graduate School of Medicine
- cNational Institute of Advanced Industrial Science and Techno
- dSendai Postal Services Agency Hospital
- eMED - Medical Sciences
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
BACKGROUND/AIMS: To clarify the distribution of CD14+ macrophages in colorectal cancer using flow cytometry and immunohistochemistry, and to elucidate the roles of CD14+ macrophages in colorectal cancer. METHODOLOGY: We studied the paired cancerous and corresponding normal tissues from 52 patients with colorectal cancer for the distribution of CD14+, CD1a+, CD83+ and CD68+ cells, and correlated the findings with the clinicopathological characteristics and with the expression of CD86 and CD80 in the CD14+ macrophages, which are co-stimulatory factors for T cell activation. RESULTS: 1) CD14+ macrophages were distributed predominantly at the invasive front of colorectal cancer tissues, rather than in the normal tissues, 2) a high percentage of the CD14+ macrophages expressed CD86 and CD80, and 3) in the colorectal cancer cases with lymph node metastasis, the 5-year overall survival rate of the high CD14 group, in which the number of CD14+ macrophages was higher than the median, was better than that of the low CD14 group. CONCLUSION: The infiltration of CD140 macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis. In addition, the activation of CD14+ macrophages and T cells may facilitate the development of new immunotherapeutic strategies for colorectal cancer patients.